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Nacre, when implanted in vivo in bones of dogs, sheep, mice, and humans, induces a biological response that includes integration
and osteogenic activity on the host tissue that seems to be activated by a set of proteins present in the nacre water-soluble matrix
(WSM). We describe here an experimental approach that can accurately identify the proteins present in the WSM of shell mollusk
nacre.Fourproteins(threegigasin-2isoformsandacystatinA2)werefortheﬁrsttimeidentiﬁedinWSMofCrassostreagigasnacre
using 2DE and LC-MS/MS for protein identiﬁcation. These proteins are thought to be involved in bone remodeling processes and
could be responsible for the biocompatibility shown between bone and nacre grafts. These results represent a contribution to the
study of shell biomineralization process and opens new perspectives for the development of new nacre biomaterials for orthopedic
applications.
1.Introduction
Bone is formed by mineral deposition (calcium phosphate
in the form of hydroxyapatite) in an organic matrix, and
materials composed of calcium phosphate are potential sub-
stitutes for bone grafts as they connect with the living tissue;
however, these materials are very fragile. Some molluscs
contain a material designated by nacre (mother-of-pearl),
a natural biomaterial formed by a regular superimposition
of polygonal aragonite calcium carbonate tablets 0.5mm
thick arranged in a brick-wall structure embedded in a
thin organic cell-free matrix layer comprising less than
2% of total weight. Nacre is considered a natural ceramic
composite with the same density of bone, and several in
vitro and in vivo studies have shown that nacre has excellent
biocompatibility and osteogenic properties suggesting its use
as a bone substitute in orthopedic surgery [1–6].
Nacre is usually composed by polygonal aragonite
platelets, each one composed by CaCO3 crystals, with a
thickness of 0,5μm and a width of 5–20μm, being orga-
nized in a columnar structure with a brick and mortar
arrangement. The organic shell matrix constitutes between
0,1–5%(w/w)ofnacreshellweight,isbelievedtobeessential
for control of shell biomineral formation, and contains
several macromolecules including polysaccharides (mostly
chitin), proteins (both water-insoluble framework proteins
and water-soluble proteins), and glycoproteins that are
presentinbothinterandintracrystallinelocationswithinthe
nacre structure. This organic matrix secreted by the external
mantle epithelium constitutes about 5% (by weight) of nacre
and the remaining 95% correspond to the aragonite platelets
[2, 3, 7–11]. Interestingly, there are reasons to believe
that although nacre is functionally and structurally similar
between diﬀerent species of bivalves (for instance, they all
contain chitin and display carbonic anhydrase activity), the
speciﬁc protein composition is quite heterogeneous across
species [12].
The most recent studies using a proteomic approach for
identiﬁcation of the proteins that constitute the extracellular
calcifying matrix of mollusks shells only conﬁrm the fol-
lowing: although dozens of diﬀerent proteins from nacreous
tissues have already been identiﬁed, there is seldom any
signiﬁcant sequence overlap between the nacre proteomes of
diﬀerent species [12–16].2 The Scientiﬁc World Journal
In vivo studies suggest the use of nacre as a biomaterial
compatible in bone repairing, since fragmented nacre from
Pinctada maxima grafted onto sheep femurs was shown
to stimulate bone repairing [4]. It is known that nacre
possesses valuable properties in terms of strength, durability,
and biologic interaction with the host’s bone. It has been
demonstrated that osteointegration of Pinctada maxima
nacre implants of long duration (9 months) occurs without
the insertion of ﬁbrous tissues [1]. In vitro studies with three
mammalian cell types: ﬁbroblasts, bone marrow stromal
cells, and osteoblasts [5, 6, 17] indicated that the water-
soluble extract of Pinctada maxima nacre matrix displays
an osteoinductor eﬀect, suggesting the existence of at least
one agent within the WSM (water-soluble matrix) with the
ability to stimulate bone formation. In vitro studies with
preosteoblastic mice cells (MC3T3-E1) also conﬁrmed that
low molecular weight molecules present in the nacre WSM
obtained from Pinctada maxima shell stimulate the diﬀer-
entiation of the preosteoblasts into osteoblasts, denoting an
inductive eﬀect in mineralization [17, 18].
WSMisconstitutedbythewater-solublemoleculesofthe
nacre organic matrix of Crassostrea gigas although its exact
composition (such as the identiﬁcation and biochemical
characterization of the agent or agents responsible for the
in vitro osteoinductive eﬀect) has not yet been achieved.
The main purpose of this work was the characterization
of the proteins contained in this matrix, as the complete
proteome of the Crassostrea gigas n a c r eW S Mh a sn o ty e t
been characterized.
2.MaterialsandMethods
2.1. Extraction of the Water-Soluble Matrix (WSM). The oys-
ters (8-9cm in length) were obtained from a local hatchery
of the Ria Formosa (Faro). The shells were thoroughly clean
from adhering soft tissues and washed with tap water. Nacre
was scratched from the inner shell layer of C. gigas oysters
and lyophilized. After lyophilisation, nacre was ground to
powder (particle size 80–100μm), and 100g of it was
suspended in 200mL of Milli-Q water for 20h at 4◦Cw i t h
constant stirring (450rpm, Stirrer ES (VELP, Scientiﬁca)).
The suspension was centrifuged at 4000rpm for 20
minutes at 4◦C, the supernatant ﬁltered through Whatman
ﬁlter paper grade 4 (20–25μmp o r e )a n ds t o r e di n2 m L
aliquots at −20◦C. The ﬁltered supernatant extract obtained
constitutes the nacre Water-soluble matrix (WSM) that was
further analyzed.
2.2.QuantiﬁcationandPuriﬁcationoftheWSMExtracts. The
total protein present in the WSM extract was quantiﬁed with
Quick Start Bradford Protein Assay kit (Bio-Rad) [19]. After
quantiﬁcation, several samples (1,76mL, 500μg total pro-
tein) were prepared and then lyophilized. To obtain samples
with low conductivity and remove ionic contaminants from
our samples, we used the ReadyPrep 2-D Cleanup Kit (Bio-
Rad, ref. 1632130) in order to purify the protein samples
for 2DE analysis. The precipitates were then solubilized in
IPG rehydration buﬀer (7M urea, 2M thiourea, 2% (w/v)
CHAPS, 50mM dithiothreitol (DTT), and 1% (v/v) IPG
PharmaLyte pH 3–10 ampholytes).
2.3. Two-Dimensional Electrophoresis (2DE). 3s a m p l e sw i t h
400μg, 280μg, and 250μg of protein, respectively, were
prepared (these samples were prepared because there is a
tradeoﬀ between the quantity of protein on the strip and
the amount of spot smearing, which results in gels with little
proteinfortheabundantproteinsandgelswithmoreprotein
for the less-abundant proteins), and the samples diluted to
a ﬁnal volume of 210μL with the ReadyPrep rehydration
buﬀercomposedof8Murea,2%CHAPS,50mMDTT,0,2%
(w/v) Bio-Lyte 3/10 ampholytes, and a trace of bromophenol
blue. The samples were added to IPG strips ReadyPrep pH
4–7, 11cm (Bio-Rad) using passive rehydration loading,
overnight at 20◦C. Isoelectric focusing (IEF) of proteins was
performed using a four-step protocol (Step 1: a gradient
from 0V to 250V over the course of 3 hours, Step 2: a
gradient from 250V to 1000V over the course of 1h 30m,
Step 3: a gradient from 1000V to 3500V over the course of
5 hours, Step 4: a step and hold at constant 3500V during
1h 13min) and a Ettan IPGphor Cell (Amersham) at a
maximum current of 50μA/strip at 20◦C. Focused strips
were stored at −20◦C until separation by second dimension.
Before the second dimension separation, the proteins on
each IPG strip were reduced for 30 minutes with 2mL of an
equilibration buﬀer (EBI) [6M urea, 2% (w/v) SDS, 0,375M
(pH 8,8) Tris-HCl, 20% (v/v) glycerol and 2% (w/v) DTT
(Bio-Rad)], and 14,81μL of DTT solution (2,7mg/μL). After
the reduction step, the EBI was removed and the proteins
on each strip alkylated for 30 minutes with 2mL of an
equilibrationbuﬀer(EBII)[6Murea,2%(w/v)SDS,0,375M
(pH 8,8) Tris-HCl, 20% (v/v) glycerol (Bio- Rad)] with 2,8%
(w/v) of iodoacetamide.
After the alkylation step, each strip was quickly washed
with MOPS running buﬀer pH 7,7 (50mM MOPS, 50mM
Tris, 0,1% (w/v), and 1mM EDTA) and loaded on 13,3 ×
8,7cm Criterion XT gels (Bio-Rad) with the wells previ-
ously ﬁlled with an agarose solution for 2DE, composed
of 0,5% (w/v) low melting point agarose, 25mM Tris,
192mM glycine, 0,1% (w/v) SDS, and vestigial quantities of
bromophenol blue (Bio-Rad). Additionally, 8μL of SeeBlue
Pre-Stained Standard (Invitrogen) were added to the gel
wherethestripcontaining250μgofproteinwasloaded.Elec-
trophoresis was then performed at 200V constant voltage in
a Criterion Cell (Bio-Rad). The gels were then rinsed with
water 3 times for 10 minutes to remove any remaining SDS.
Gels were placed in a solution of 50% (v/v) methanol and
10% (v/v) acetic acid for 15 minutes and then rinsed with
waterfor15minutes. Staining wasperformedovernight with
colloidal Coomassie brilliant blue G-250 (EZBlue (Sigma))
and then washed with deionized water.
2 . 4 .I d e n t i ﬁ c a t i o no ft h eW S MP r o t e i n sb yM a s sS p e c t r o m e t r y
(LC-MS/MS). Protein spots were excised and stored in
Eppendorfs tubes with 20μL of Milli-Q water at −80◦C.
EightofthesespotswereselectedandanalyzedbyLC-MS/MS
at the Aberdeen Proteomics facilities.The Scientiﬁc World Journal 3
The proteins in the protein spots were reduced and alky-
lated (with DTT and iodoacetamide, resp.). Each reduced
and alkylated protein was then subjected to tryptic digestion
(using an autolysis-resistant modiﬁed trypsin) and the
resulting peptides were extracted with formic acid and
acetonitrile. The peptides were then analyzed in an UltiMate
3000LC System (Dionex) coupled to a HCTultra PTM
Discovery System (spherical ion trap) with a low-ﬂow
nebulizer (Bruker Daltonics). The liquid chromatography
separation was performed using a PepSwift monolithic
PS-DVB capillary column (200μmi . d .× 5cm; Dionex),
2,0μL/min ﬂow rate, and a linear gradient of acetonitrile.
Peptide peaks were detected and deconvoluted automatically
using DataAnalysis software (Bruker Daltonics). At the end
of the run, mass lists in the form of Mascot Generic Files
(.mgf) were created automatically.
The mass lists generated in the previous step were
then used as an input to Peptide Fragment Fingerprinting
(PFF) searches on the nonredundant database of NCBI
(NCBInr) using the Matrix Science webserver (http://www
.matrixscience.com/). The search was performed on the
NCBInr database assuming the carbamidomethylation of
cysteine residues, the formation of double or triple charged
peptides, allowing up to 1 missed cleavages, oxidation of
methionine residues, carboxylation of glutamate residues, a
1,5Da peptide mass tolerance and a 0,5Da MS/MS mass
tolerance and the taxonomy as “other Metazoa”. When-
ever no signiﬁcant results were obtained with the NCBInr
database, searches in the EST others database were per-
formed afterwards. Due to the fact that ESTs are seldom
properly annotated, the resulting sequences were then com-
pared to the NCBInr protein sequences (using BLASTP,
http://blast.ncbi.nlm.nih.gov/) in order to ﬁnd proteins
with signiﬁcantly similar sequences. Reﬁnement of iden-
tiﬁcations towards particular isoforms was conﬁrmed by
performing multiple alignments using MCOFFEE (http://
www.tcoﬀee.org/).Additionally,automateddetectionofcon-
served domains and motifs was performed using Inter-
ProScan (http://www.ebi.ac.uk/Tools/pfa/iprscan/)a n dE L M
(http://elm.eu.org/)[ 20].
3. Results
From the 3 electrophoresis gels performed, two were used to
excise the spots for LC-MS/MS analysis and one containing
the prestained molecular weight markers was used to esti-
mate the molecular weight of the spots. Figure 1 represents
a 2D gel (pH 4–7 11cm, Bis-tris 12%) of WSM Crassostrea
gigas nacre where spots selected for mass spectrometry
analysis are numbered. WSM 2, 3, 4, 7, 8, 13, 14, and 52
(Figure 1)representthe2Dproteinspotsselectedforidentiﬁ-
cation.
TheW SMspots2,3,4,7,8,14,and52(molecularw eight
between 19kDa and 38kDa, Figure 1), shown to be well
resolved in 2-DE gel, were also selected for sequence analysis
because there were some reports that described a 19kDa
protein from oyster Pinctada fucata, denominated N19,
having a role as negative regulator of pearl calciﬁcation [21].
2 3 4 7
13
14
52 8
18
6
28
38
62
188
Mw
Figure 1: 2DE gel (11cm, pH 4–7, Bis-Tris 12%) showing all the
protein spots detected in nacre WSM from Crassostrea gigas. Num-
bered spots represent proteins identiﬁed by mass spectrometry.
Until now, N19 has only been identiﬁed in the water-
insoluble matrix; however, it seemed relevant to see if any
of these unidentiﬁed proteins with similar molecular weights
could have some role in the biomineralisation processes.
Recent works using two mineralogenic cell lines have
shown that a protein-denominated p10 obtained from
Pinctada fucata oyster, with a molecular weight around
10kDa, could accelerate the nucleation of the calcium
carbonate crystals, inducing the formation of aragonite,
suggesting that this p10 protein could play an important
role in nacre biomineralisation. The protein was also shown
to induce osteoblast diﬀerentiation, since the results also
showed increased ALP activity [22]. The conjugation of this
data led us to further select the WSM 13 spot (Figure 1)f o r
sequence by LC-MS/MS.
After LC MS/MS analysis of the spots, the data obtained
was processed with the MASCOT search engine as described
in Materials and Methods section. Eight spots were iden-
tiﬁed with a high degree of certainty as homologous to
certain EST sequences by peptide fragment ﬁngerprint-
ing (PFF). Identiﬁcation was then performed by BLASTp
alignment of obtained EST sequences (Table 1) against the
NCBInr database, using the default settings (http://www
.ncbi.nlm.nih.gov/blast/Blast.cgi). Signiﬁcant matches (E-
value < 0.05) were then conﬁrmed by making sure identiﬁed
peptides were present in the matched sequences, as well
as by performing multiple alignments and domain/motif
prediction analysis. In some cases, the same protein was
identiﬁed in more than one gel spot of similar molecular
mass (Figure 1, Table 1). These may represent a PTM such as
phosphorylation or proteolysis. Table 2 contains a summary
of the proteins identiﬁed on the eight spots selected for
analysis after the BLASTp alignment and complementary
analyses.
4. Discussion
A total of four proteins present in the WSM nacre obtained
from Crassostrea gigas were identiﬁed using a 2DE and LC-
MS/MS approach, although one of them has already been4 The Scientiﬁc World Journal
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Table 2: Putative identity of the proteins identiﬁed by mass spectrometry (LC-MS/MS). Hits with the lowest E-value are represented which
are proteins with the biggest homology to the peptides obtained from LC-MS/MS. The emPAI (Exponentially Modiﬁed Protein Abundance
Index) value oﬀers approximate, label-free, relative quantitation of the proteins in a mixture based on protein coverage by the peptide
matches in a database search result [23].
Spots
[EST Accession Number] Putative identity emPAI score
WSM 2 [gi|164576479] Peptidylprolyl isomerase B/cyclophilin B 0,28
WSM 2 [gi|164584223] Gigasin-2 0,70
WSM 2 [gi|164584724] Gigasin-2 1,47
WSM 3 [gi|164576479] Peptidylprolyl isomerase B / cyclophilin B 0,13
WSM 3 [gi|164584223] Gigasin-2 0,70
WSM 3 [gi|164584724] Gigasin-2 1,47
WSM 4 [gi|115724273] Putative serine/threonine-speciﬁc protein kinase 0,11
WSM 4 [gi|164582888] Gigasin-2 like 1,25
WSM 4 [gi|168810136] Gigasin-2 like 0,43
WSM 7 [gi|164582888] Gigasin-2 like 0,97
WSM 7 [gi|168810136] Gigasin-2 like 0,71
WSM 8 [gi|14581004] PLCPI = cysteine proteinase inhibitor/cystatin A (steﬁn A) 0,16
WSM 8 [gi|164570244] Cystatin A2 0,62
WSM 13 [gi|14581004] PLCPI = cysteine proteinase inhibitor/cystatin A (steﬁn A) 0,16
WSM 13 [gi|164570244] Cystatin A2 0,62
WSM 14 [gi|152813529] Similar to Potassium channel subfamily K member 9 0,32
WSM 14 [gi|164582378] Gigasin-2 like 4,19
WSM 52 [gi|164582378] Gigasin-2 like 1,28
identiﬁed in the insoluble fraction of Crassostrea gigas nacre
matrix. After 2DE separation, selected spots (Figure 1)w e r e
identiﬁedbyhomologyasthreeisoformsofGigasin-2(WSM
2 and WSM 3, WSM 4 and WSM 7, WSM 14 and 52) and
cystatin A2 (WSM 8 and WSM 13). These proteins were
found to be the most abundant in each of the excised spots,
according to the respective emPAI (exponentially modiﬁed
protein abundance index) values, which constitute a label-
free estimate of the abundance of each protein within each
spot [23].
One of the gigasin-2 isoform identiﬁed (corresponding
toWSM2andWSM3)hasalreadybeenpreviouslydescribed
by Marie et al. [24] as being present in the insoluble fraction
of C. gigas nacre matrix, while the other two identiﬁed
isoforms (corresponding to WSM4/7 and WSM 14/52) have
not been previously identiﬁed. Gigasin-2 contains two con-
served EGF domains, being somewhat homologous to Wnt
inhibitory factor-1 (WIF-1) and tenascin C. Wnt inhibitor
factor-1 is well described as an evolutionary conserved
protein, member of the secretory Wnt modulators, which
contains a single WIF domain that mediates Wnt direct
binding, and ﬁve epidermal growth factor-like repeats [25].
Wnt proteins belong to a family of nineteen secreted
glycoproteins, associated with the regulation of several
development processes like embryogenesis, organogenesis,
and oncogenesis [26–32]. The signalling of Wnt that results
in tissue-speciﬁc activation of target gene transcription is
initiated by the binding of Wnts ligands to Frizzled receptors
and the coreceptor lipoprotein receptor-related protein 5/6
(LRP5/6). This metabolic pathway is also regulated by
the secretion of antagonists that prevent ligand-receptor
interaction, binding directly to the Wnt proteins or to
the LRP5/6 component of the Wnt receptor complex [32].
These interactions activate multiple intracellular signalling
cascades that include the canonical/β-catenin pathway which
is the most studied Wnt signalling pathway. Wnts and its
membrane receptor complex are known to be expressed in
bone, and it is now widely established that this family of
growthfactorsplaysacentralroleinregulationofbone,bone
remodeling, and bone regeneration [33–37].
Clinical results have identiﬁed in human, a link between
bone mass and mutations in LRP-5 with loss of function
causing osteoporosis pseudoglioma syndrome and gain of
function leading to pathological thickening of bone [38, 39].
Genetic studies with knockout and transgenic mouse models
for Wnt pathway components have also demonstrated
that this signaling pathway modulates the most important
osteoblast physiologic processes, including proliferation,
diﬀerentiation, and bone matrix mineralization as well as
inhibiting bone-resorbing osteoclast function (for reviews
see [35, 37]).
WIF-1’s role in Wnt signalling was ﬁrst described in
human retina with very well-conserved orthologous proteins
also identiﬁed in Xenopusa n dZebraﬁsh [40], and although
only limited data are available on the role of the Wnt
antagonist WIF-1 in osteoblasts, a recent study indicates that6 The Scientiﬁc World Journal
WIF-1 plays a role as a negative regulator of osteoblastic
diﬀerentiation in mouse mesenchymal C3H10T1/2 cells in
vitro [36].
Altogether the available information on canonical Wnt
signalingasaboneformationregulatorandtheidentiﬁcation
in nacre WSM (Figure 1) of proteins homologous to Wnt
inhibitory factor-1 leads us to suggest that Wnt antagonists
present in nacre may be related to the WSM nacre known
osteogenic activity although further studies are necessary in
order to understand the role of WIF-1 in bone development.
Tenascins are a glycoprotein family associated with the
organic extracellular matrix (ECM), that induce prolifera-
tion, diﬀerentiation and cellular migration [41–43]. Four
members of this family (tenascins C, R, X and W) have
been identiﬁed and characterized in vertebrates [44]. The
basic structure of tenascins are composed by epidermal
growth factor (EGF) repeats in the direction of the amino
end, ﬁbronectin type III domains and a globular ﬁbrinogen
domain in the carboxylic end. Diﬀerences in both the num-
ber and nature of EGF and ﬁbronectin type III domains can
be observed between diﬀerent species [41, 42]. Tenascin C is
adisulﬁdehexamer,withacysteine-richcenter,composedby
subunitswithamolecularmassofapproximatelyof200kDa.
Thesesubunitscanhavediﬀerentmassesduetoglycosylation
[41]. In mammals, the subunits are constituted by 14.5 EGF
repeats with 8 ﬁbronectin type III domains present in all the
tenascin C isoforms [45].
Tenascin C is abundant in ECM both during connective
tissue and bone development [46]. It is also found in
ECM during smooth muscle development and expressed in
kidneycells[47].TenascinCfavorsosteoblastdiﬀerentiation,
increasing ALP activity, as well as in vitro synthesis of
speciﬁc bone proteins [48]. It also promotes proliferation of
ﬁbroblasts [49], smooth muscle [50] and tumor cells [51].
The mechanism of action underlying Tenascin C eﬀect on
cells is still unknown and is currently being investigated.
It was found that the EGF repetitions of this protein can
bind the EGF receptors and activate them [52]. It has also
been reported that Tenascin C is able to induce growth-
stimulatingmechanismsliketheWntsignalingpathway[53].
We can then assume that the identiﬁed Gigasin-2 pro-
teins(whichdisplayhomologytoproteinssuchasWIF-1and
TenascinC)mightnotonlybeoneoftheproteinsresponsible
for the observed biocompatibility of nacre grafts in bone,
but may also have a relevant role in shell mineralization of
Crassostrea gigas.
The protein identiﬁcation results obtained for spots
WSM 8 and 13 were matched as having homology to
Cystatin A2. Cystatins are a family of proteins well known
as inhibitors of cysteine proteinases (for review see [54]),
and this family is widely shown to be present in diﬀerent
organisms including animals and plants [55]. Besides this
inhibitory common function, these proteins are organized
in three diﬀerent families with high structural diversity that
range, in family 1 cystatins, from 11kDa unglycosylated
intracellular proteins lacking disulﬁde bonds, like cystatins
A and B, through family 2 cystatin secreted proteins, pre-
senting with slightly higher molecular masses (13-14kDa),
sometimes glycosylated and containing disulﬁde bonds, as,
for example, cystatin C. A third family includes much higher
molecular weight complex proteins comprising three family-
2 cystatin domains, disulﬁde bonds, and carbohydrate
groups. Nonetheless, all these cystatin superfamily members
include a conserved motif, namely, a Gln-Xaa-Val-Xaa-Gly
motif in the central region of the polypeptide chain (where
Xaa is any amino acid) [56, 57] that our results conﬁrmed
to be present in WSM 8 and 13. Cystatins mainly interact
with the cysteine proteases papain and the mammalian
cathepsins B, H, K, L, and S and are also known to inactivate
cysteine proteinases released by invading microorganisms
and parasites [57–59]. The presently identiﬁed cystatin A2
isoform could preclude that cystatin B may also be present
in nacre since these proteins are structurally very similar.
The identiﬁcation in oyster and Manila clam of ESTs with
sequence similarity to cystatin B reinforces our hypothesis
[60–62].
Cystatin A has been also suggested to have a defense
function against exogenous pathogens [57–59]. On the other
hand, cystatin B is broadly distributed on cells and tissues
and is considered a general cytosolic inhibitor, protecting
cells against proteolytic degradation by cathepsins. The
presenceofcystatinA2inC.gigasnacremayhaveaprotective
role in the organism since cystatins A inhibit cysteine
proteinases from invading microorganisms and parasites.
Interestingly, the eﬀect of cystatin C on calvarial bone
formationwasexaminedinexvivoandinvitroculturemouse
systems, and the results showed that this protein stimulates
osteoblast diﬀerentiation and bone formation [63, 64]. Also
cystatin B may help regulating bone resorption by blocking
the activity of cathepsin K in osteoclasts [65].
Cysteine cathepsins can be found in all living cells
and constitute a wide protease family for which a wide
range inhibitors including cystatins have been published
and used (for review see [66]). Cathepsin K is a well-
described cysteine protease mainly involved in collagen type
I degradation in bone and teeth and highly expressed in
human osteoclasts [67, 68]. Cathepsin K knockout mice
were shown to develop osteopetrosis caused by impaired
osteoclastic bone resorption, and these results conﬁrmed the
role of these proteases in bone degradation processes. In fact,
several studies report the eﬀect of cathepsin K inhibitors
on the reduction of biomarkers of bone resorption both in
vitro and in vivo [69, 70]. More recently, ovariectomized
cynomolgus monkey, a known postmenopausal osteoporosis
model,wassubjecttoalong-termtreatmentwithacathepsin
K inhibitor and showed an unexpected stimulatory eﬀect on
periosteal bone formation [71].
The inhibition of serine and cysteine proteases, namely,
K proteinase, by the WSM nacre fraction was previously
observed by B´ edouet et al. reinforcing our belief that cystatin
A2 might be one of the proteins involved in bone resorption
[72]. Recently, other protease inhibitors have been identiﬁed
by Marie et al. on the nacre of various mollusks [12, 14, 15],
and they propose that the role of these protease inhibitors
could be the protection of the organic matrix against
degradation by exopeptidases, but they can also suggest a
role in the remodeling of the shell matrix. We believe that
these proteases identiﬁed in other mollusks may also beThe Scientiﬁc World Journal 7
present in the C. gigas nacre WSM extract, since we still
have unidentiﬁed protein spots in our 2DE, with molecular
weights similar to the previously described [14, 15]. In
addition,spotsWSM8and13showadiﬀerentgelmigrations
behavior corresponding to diﬀerent molecular weights, and
this fact is consistent with the possibility that spot WSM 13
is a fragment of the identiﬁed spot WSM 8 protein, since
its theoretical molecular weight obtained from the EST is
identical to the result obtained from spot WSM 8. Although
type1 cystatins have a molecular weight similar to spot WSM
13, we believe that, in this case, the identiﬁed cystatin has a
molecular weight correspondent to 22kDa. This observation
is consistent with known literature since there are plant
cystatins that have a similar molecular weight, raising the
hypothesis that oyster cystatins might have evolved similarly
(withtheaugmentationofthemolecularweightexplainedby
intragenic duplication eﬀects) [55, 73, 74].
In conclusion, during this work, four proteins (three
Gigasin-2 isoforms and one cystatin A2) were identiﬁed and
proven to be present in WSM of the nacre of the oyster
Crassostrea gigas. These are thought to be involved in bone
remodeling processes, and some could have a role in the
biocompatibility shown between bone and nacre grafts. In
the future, these proteins and also the remaining proteins
p r e s e n ti nt h eW S Mo fn a c r ea r ee x p e c t e dt ob ei d e n t i ﬁ e d
and their osteogenic and osteoinductive properties tested in
cell lines to verify if it is their combined eﬀect that induces
the bone remodeling or if they have an eﬀect on their own.
Unsurprisingly, only one of the four proteins identiﬁed in
this work was previously identiﬁed, at the protein level, in
the nacre of bivalves (speciﬁcally, in the insoluble fraction
of G. gigas nacre matrix), which underlines the need for
further studies elucidating the protein content of bivalve
nacre matrix.
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